Concord Wealth Partners Cellectis S.A. Transaction History

Concord Wealth Partners

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 21, 2022	SELL	$8.01 - $12.84 $2,106 - $3,376	-263 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$11.94 - $16.09 $2,793 - $3,765	-234 Reduced 47.08%	263 $3,000
Q2 2021 Jul 29, 2021	BUY	$14.36 - $20.93 $6,519 - $9,502	454 Added 1055.81%	497 $8,000
Q1 2021 May 13, 2021	BUY	$18.19 - $33.25 $363 - $665	20 Added 86.96%	43 $1,000
Q4 2020 Feb 16, 2021	BUY	$15.87 - $31.64 $365 - $727	23 New	23 $1,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Concord Wealth Partners, based on Form 13F filings with the SEC.

Stay updated on Concord Wealth Partners with notifications on news.